In the group of training, no statistically significant differences were observed in gender, age, tumor stage, LYM, ALB level, D-D level, EBV-DNA antibody level, or LDH level across different therapeutic response groups (all p > 0.05). The gene discussed is ALB; the disease is neoplasm.